全文获取类型
收费全文 | 2145篇 |
免费 | 170篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 154篇 |
妇产科学 | 49篇 |
基础医学 | 234篇 |
口腔科学 | 14篇 |
临床医学 | 338篇 |
内科学 | 329篇 |
皮肤病学 | 32篇 |
神经病学 | 161篇 |
特种医学 | 5篇 |
外科学 | 279篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 298篇 |
眼科学 | 18篇 |
药学 | 126篇 |
中国医学 | 3篇 |
肿瘤学 | 245篇 |
出版年
2023年 | 26篇 |
2022年 | 28篇 |
2021年 | 52篇 |
2020年 | 32篇 |
2019年 | 48篇 |
2018年 | 51篇 |
2017年 | 46篇 |
2016年 | 61篇 |
2015年 | 66篇 |
2014年 | 83篇 |
2013年 | 114篇 |
2012年 | 149篇 |
2011年 | 154篇 |
2010年 | 82篇 |
2009年 | 71篇 |
2008年 | 118篇 |
2007年 | 122篇 |
2006年 | 116篇 |
2005年 | 140篇 |
2004年 | 112篇 |
2003年 | 118篇 |
2002年 | 105篇 |
2001年 | 13篇 |
2000年 | 9篇 |
1999年 | 13篇 |
1998年 | 19篇 |
1997年 | 18篇 |
1996年 | 14篇 |
1995年 | 17篇 |
1994年 | 10篇 |
1993年 | 20篇 |
1992年 | 18篇 |
1991年 | 10篇 |
1990年 | 17篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1978年 | 11篇 |
1977年 | 11篇 |
1974年 | 7篇 |
1973年 | 8篇 |
1972年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有2321条查询结果,搜索用时 15 毫秒
1.
2.
Lillian Comas-Diaz 《Clinical psychology》2006,13(3):273-277
This article discusses clinical psychologists' current concerns, challenges, and opportunities in private practice. The future of clinicians in independent practice is presented within two paradigms, namely, psychology as a health profession, and psychology as life enhancement. Finally, the author argues that psychotechnology, corporate clinical psychology, and psychology as life enrichment will evolve within the future of clinical psychological independent practice. 相似文献
3.
Azra M. Sehic Lillian W. Gaber Shane Roy III Paula M. Miller Stephen B. Kritchevsky Robert J. Wyatt 《Pediatric nephrology (Berlin, Germany)》1997,11(4):435-437
Based upon the percentage of cases of IgA nephropathy (IgAN) in biopsy series, a lower prevalence has been assumed for African-Americans
compared with Americans of European descent. This may be due to a racial difference in the basic underlying pathology of IgAN
or to racial differences in patterns of referral and biopsy selection practices. Over the past decade (1985 – 1994), we have
found similar incidences of IgAN in Caucasian and African-American children from Shelby County, Tennessee. The incidence was
3.0 cases per million per year for Caucasian and 5.7 cases per million per year for African-American children. IgAN may be
more common in African-American children than previously appreciated. Population-based incidence studies will be necessary
to determine whether or not our experience has become a more widespread phenomenon.
Received August 21, 1996; received in revised form and accepted December 18, 1996 相似文献
4.
Manohar Bance Alfredo Campos Lillian Wong David P Morris Rene van Wijhe 《Otolaryngology--head and neck surgery》2007,137(1):70-73
OBJECTIVES: The transmission of vibrations from the tympanic membrane to the stapes footplate by an ossicular reconstruction prosthesis is affected by the size of the prosthesis head. We sought to determine if augmenting or reducing the head size of prosthesis had a systematic effect on transmission of vibrations to the stapes. STUDY DESIGN: We conducted a fresh cadaveric temporal bone middle ear study. METHODS: The incus was replaced with a prosthesis using a tympanic membrane to stapes head (TASH)-type hydroxyapatite prosthesis in nine fresh cadaveric temporal bones. Three prosthesis head sizes were created: unaltered, reduced, and augmented. Stapes vibrations were measured with a laser Doppler vibrometer in response to acoustic frequency chirps at 90 dB SPL. RESULTS: All three head size prostheses resulted in smaller stapes vibrations than the intact ear. There was no difference in the vibration transmission between the three different head sizes. All prostheses showed a vibration loss of 10 to 15 dB compared to the intact ear. CONCLUSIONS AND SIGNIFICANCE: Within the range of sizes tested, prosthesis head size had little impact on vibration transmission to the stapes footplate. 相似文献
5.
Lillian L. L. Leong Marian J. Sturm Yahya Ismail Charlene J. Stephens Roger R. Taylor 《Clinical and experimental pharmacology & physiology》1992,19(2):113-118
1. Phospholipase A2 (PLA2) cleaves phospholipids to produce a lyso-phospholipid and free fatty acid and, in view of the biological activity of the products, PLA2 may play a role in many disease states. Lyso-phospholipids and free arachidonic acid increase in ischaemic myocardium, indicating that ischaemia activates the enzyme. 2. Plasma PLA2 activity was measured in patients with acute myocardial infarction, based on the release of labelled arachidonic acid from Escherichia coli cell membrane. Fourteen males (peak serum creatine phosphokinase (CK) above twice upper normal) were studied on day 1 (within 6 h of chest pain onset), days 2-4, and days 6-9. Normal age matched males (n = 13) were also studied. 3. Plasma PLA2 in patients with uncomplicated myocardial infarction (n = 12) was, initially, 1.14 +/- 0.10 (s.e.m.) nmol/min per mL plasma, similar to that in the normal group (1.52 +/- 0.14). On days 2-4, PLA2 activity increased to 1.94 +/- 0.18 (P less than 0.001) and this activity was correlated with the earlier peak CK level (P less than 0.02). On days 6-9, PLA2 activity was 1.49 +/- 0.13 while in two patients who developed complications and underwent open-heart surgery between the last two measurements, there were further increases to 4.22 and 4.04 nmol/min per mL. 4. The increase in plasma PLA2 in uncomplicated myocardial infarction is likely to be due to release from the damaged myocardium; whether it contributes to pathophysiology is uncertain. 相似文献
6.
HLA-A and -B alleles in 74 Danish patients and 21 homozygous relatives with idiopathic haemochromatosis (IH) were compared with those in a sample of 1719 chromosomes from healthy Danish control subjects. The following alleles occurred with higher frequencies in IH compared to controls: A3: 53.6% vs. 15.1% (Pc less than 0.001); B7: 33.1% vs. 15.6% (Pc less than 0.001); B14: 6.9% vs. 3.0% (Pc greater than 0.05); B38: 5% vs. 0.9% (Pc greater than 0.05); B47: 4.0% vs. 0.4% (Pc greater than 0.05). Pedigree analyses disclosed 19 different haplotypes in IH subjects, compared to 286 haplotypes in controls. The following haplotypes occurred with higher frequency in IH compared to controls: A3,B5: 10.3% vs. 0.3% (Pc less than 0.001); A3,B7: 25.6% vs. 6.6% (Pc = 0.001); A3,B14: 3.4% vs. 0.6% (Pc greater than 0.05); A3,B47: 6.9% vs. 0.2% (Pc greater than 0.05). The major IH marker HLA-A3 was found in 56% of the haplotypes. The patterns of HLA-alleles associated with IH in Denmark show similarities to those in Central Europe, Australia, USA and Canada, being A3,B7 dominated and those in Central Sweden, England and Ireland, being A3,B14 dominated. 相似文献
7.
Barbara H. Bowman Lillian H. Lockhart Victoria L. Herzberg Don R. Barnett Donald Armstrong John Kramer 《Clinical genetics》1973,4(6):461-463
The presence of a ciliary inhibitor in media of cultured amniotic cells obtained from a fetus heterozygous for cystic fibrosis has been observed by the oyster gill cilia assay. The chromatographic fraction containing the inhibitor corresponded to eluted fractions chromatographed from cystic fibrosis fibroblast media and serum. An analogous chromatographic fraction from media of cultured amniotic cells from two proportedly normal fetuses did not inhibit cilia. The chromatographic fraction from media of cultured amniotic cells of a fetus at high risk for cystic fibrosis did not inhibit ciliary activity. Serum was collected from this baby seven weeks after birth and also did not inhibit ciliary action, indicating a homozygous normal genotype. These observations may lead to the development of an antenatal test for cystic fibrosis. 相似文献
8.
9.
We have studied a patient with clinically established Fanconi type anemia whose peripheral blood leukocyte culture and bone marrow showed a normal male karyotype, with no morphological alterations. The skin fibroblasts in cultures derived from his father, however, revealed a mosaic pattern, 47 , XY F+/46, XY. The findings of a trisomic cell line in a parent of a patient with Fanconi's anemia has been reported only once before. 相似文献
10.
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. 总被引:11,自引:0,他引:11
Shazli N Malik Lillian L Siu Eric K Rowinsky Linda deGraffenried Lisa A Hammond Jinee Rizzo Sarah Bacus Michael G Brattain Jeffrey I Kreisberg Manuel Hidalgo 《Clinical cancer research》2003,9(7):2478-2486
BACKGROUND: OSI-774 is an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) currently in clinical development. In preclinical models, the antitumor activity of OSI-774 was directly related to its ability to inhibit the EGFR-TK. On the basis of these data, we hypothesized that inhibition of the EGFR-TK will be required for this agent to be effective in the clinic. This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study. METHODS: Patients with advanced cancer who were treated in a Phase I study of OSI-774 underwent a biopsy of normal skin epidermis at baseline and after the last dose of drug in the first course of treatment. The expression and activation of the EGFR, downstream signaling extracytoplasmatic-regulated kinase (Erk), and cell cycle regulator p27 were determined in paraffin-embedded skin tissues using an immunohistochemical method (IHC). The IHC data were analyzed using both a semiquantitative scoring system and an automatic absorbance quantitative IHC method. The number of cells with nuclear staining of p27 per 500 cells was determined. Plasma samples were collected to quantitate OSI-774 plasma concentrations. RESULTS: A total of 56 skin specimens was collected from 28 patients treated with OSI-774 at doses ranging from 25 to 200 mg/day. There was a significant decrease in phospho-EGFR (Tyr 1173) expression as determined semiquantitatively with OSI-774 treatment [2.75 +/- 0.51 (mean +/- SD) pretreatment versus 2.36 +/- 0.76 after treatment, pair comparison P = 0.01]. The quantitative ratio [(phopho-EGFR/EGFR) x 100] of phospho-EGFR (Tyr1173) decreased from 64.16 +/- 36.58 pretreatment to 48.87 +/- 35.37 post-treatment (pair comparison, P = 0.02). No significant differences were observed in phospho-Erk (Thr202/Tyr204) expression. The mean number of cells with nuclear staining for p27 increased from 185 +/- 101 (mean +/- SD) pretreatment to 253 +/- 111 post-treatment (pair comparison P = 0.02). A total of 12 (42.8%), 7 (25%), and 14 (50%) patients had >25% variation in the ratio of phospho-EGFR (Tyr1173), phospho-Erk (Thr202/Tyr204), and p27 expression, respectively. Only changes in p27 expression were related to the administered dose of OSI-774. CONCLUSIONS: OSI-774 exerted pharmacodynamic effects in skin tissues of 30-50% of patients treated with the agent. Up-regulation of p27, which is a downstream effect of EGFR inhibition, was dose related. Although there was a significant decrement in phospho-EGFR (Tyr1173), it was not related to the administered dose of OSI-774. On the basis of these findings and the relatively simple and reliable method to measure p27 expression, this biomarker appears to be the most promising and is being evaluated in Phase II studies as a predictor of clinical outcome. 相似文献